Logo Logo

Publications by Vehling-Kaiser, Ursula

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 9.

Journal article

Holch, Julian W.; Ricard, Ingrid; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Scholz, Michael; Müller, Sebastian; Link, Hartmut; Rost, Andreas; Höffkes, Heinz-Gert; Moehler, Markus; Lindig, Reinhard Udo; Miller-Phillips, Lisa; Kirchner, Thomas; Jung, Andreas; Einem, Jobst C. von; Modest, Dominik Paul; Heinemann, Volker (2018): Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial. In: International Journal of Cancer, Vol. 142, No. 5: pp. 1047-1055

Stahler, Arndt; Heinemann, Volker; Neumann, Jens; Crispin, Alexander; Schalhorn, Andreas; Stintzing, Sebastian; Giessen-Jung, Clemens; Fischer von Weikersthal, Ludwig; Vehling-Kaiser, Ursula; Stauch, Martina; Quietzsch, Detlef; Holch, Julian W.; Kruger, Stephan; Haas, Michael; Michl, Marlies; Einem, Jobst von; Kirchner, Thomas; Jung, Andreas; Modest, Dominik P. (2017): Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer. In: Anti-cancer drugs, Vol. 28, No. 7: pp. 717-722 [PDF, 422kB]

Modest, Dominik P.; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Scheithauer, Werner; Kirchner, Thomas; Jung, Andreas; Stauch, Martina; Einem, Jobst Christian von; Möhler, Markus; Held, Swantje; Heinemann, Volker (2017): Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306). In: International Journal of Cancer, Vol. 140, No. 8: pp. 1918-1925

Modest, Dominik Paul; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Sobrero, Alberto F.; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Seipelt, Gernot; Lerchenmüller, Christian A.; Kahl, Christoph; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Swantje; Moehler, Markus H.; Jung, Andreas; Kirchner, Thomas; Heinemann, Volker (2016): Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS wild-type metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab). In: Journal of Clinical Oncology, Vol. 34, No. 4

Stintzing, Sebastian; Modest, Dominik P.; Rossius, Lisa; Lerch, Markus M.; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Held, Swantje; Giessen-Jung, Clemens; Moehler, Markus; Jagenburg, Andreas; Kirchner, Thomas; Jung, Andreas; Heinemann, Volker (2016): FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. In: Lancet Oncology, Vol. 17, No. 10: pp. 1426-1434

Ormanns, Steffen; Siveke, Jens T.; Heinemann, Volker; Haas, Michael; Sipos, Bence; Schlitter, Anna Melissa; Esposito, Irene; Jung, Andreas; Laubender, Rüdiger P.; Kruger, Stephan; Vehling-Kaiser, Ursula; Winkelmann, Cornelia; Fischer von Weikersthal, Ludwig; Clemens, Michael R.; Gauler, Thomas C.; Märten, Angela; Geissler, Michael; Greten, Tim F.; Kirchner, Thomas; Boeck, Stefan (2014): pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. In: BMC Cancer 14:624 [PDF, 408kB]

Modest, Dominik P.; Schulz, Christoph; Fischer von Weikersthal, Ludwig; Quietzsch, Detlef; Einem, J. C. von; Schalhorn, Andreas; Vehling-Kaiser, Ursula; Laubender, Rüdiger P.; Giessen, Clemens; Stintzing, Sebastian; Heinemann, Volker (2014): Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment). In: Anticancer Drugs, Vol. 25, No. 2: pp. 212-218 [PDF, 442kB]

Heinemann, Volker; Vehling-Kaiser, Ursula; Waldschmidt, Dirk; Kettner, Erika; Märten, Angela; Winkelmann, Cornelia; Klein, Stefan; Kojouharoff, Georgi; Gauler, Thomas C.; Fischer von Weikersthal, Ludwig; Clemens, Michael R.; Geissler, Michael; Greten, Tim F.; Hegewisch-Becker, Susanna; Rubanov, Oleg; Baake, Gerold; Höhler, Thomas; Ko, Yon D.; Jung, Andreas; Neugebauer, Sascha; Böck, Stefan (May 2013): Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the `Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). In: Gut, Vol. 62, No. 5: pp. 751-759 [PDF, 468kB]

Giessen, Clemens; Fischer von Weikersthal, Ludwig; Hinke, Axel; Stintzing, Sebastian; Kullmann, Frank; Vehling-Kaiser, Ursula; Mayerle, Julia; Bangerter, Markus; Denzlinger, Claudio; Sieber, Markus; Teschendorf, Christian; Freiberg-Richter, Jens; Schulz, Christoph; Modest, Dominik Paul; Moosmann, Nicolas; Aubele, Philipp; Heinemann, Volker (2011): A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial. In: BMC Cancer 11:367 [PDF, 533kB]

This list was generated on Mon Sep 23 07:26:12 2019 CEST.